View Pages
Target Raises Guidance After Comp Sales Beat; Lowe’s Cuts Outlook; Moderna Surges
Target lifts full-year sales outlook after Q2 comp-sales beat; Lowe’s trims guidance amid weak housing; Moderna jumps on promising melanoma vaccine trial.
Editorial companion
What stands out
Target reported comparable sales that beat estimates and lifted its full-year guide, yet the market’s reaction looks cautious. Bloomberg’s Stock Movers used that result to highlight a larger theme: pockets of retail strength amid wider consumer unevenness, with Lowe’s trimming outlook and Moderna roaring on a clinical read. For investors it is a classic two-step: better comps and firmer margins on one hand, still a negative revenue trend and a bearish combined outlook on the other, so this feels like recovery work-in-progress.